Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-382P is a **pseudogene derived from the U6 small nuclear RNA gene family**. U6 snRNA is a highly conserved and essential component of the spliceosome, the cellular machinery responsible for pre-mRNA splicing in eukaryotes[1][3]. While functional U6 snRNA plays a critical catalytic role in intron excision and RNA processing[1][3], this specific pseudogene variant, "RNA, U6 small nuclear 382, pseudogene", is presumed non-functional: it does not produce a mature RNA molecule or protein, nor does it participate in spliceosomal functions. Pseudogenes like RNU6-382P may arise during genome evolution due to gene duplication or retrotransposition events, and they are distinguished from their functional counterparts by mutations, truncations, or regulatory disruptions that prevent their expression or activity[4]. Most U6 pseudogenes are considered **"genomic relics"**, although some pseudogenes are now recognized to have limited regulatory effects, such as modulating parental gene expression via RNA interference or acting as microRNA decoys in rare contexts[4]. These functions are **not established for RNU6-382P**. **In summary:** RNU6-382P is a noncoding pseudogene related to spliceosomal U6 snRNA, not a receptor, enzyme, or direct therapeutic target. There is no evidence for biological, disease, or therapeutic relevance specific to this pseudogene. Its listing as a target may reflect a database artifact or misinterpretation of the nomenclature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 382, pseudogene (RNU6-382P).